AURO-VALSARTAN HCT 25 MG
HYDROCHLOROTHIAZIDE : 25 MG VALSARTAN : 160 MG · DIN 02408139 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-VALSARTAN HCT?
AURO-VALSARTAN HCT 25 MG contains HYDROCHLOROTHIAZIDE : 25 MG VALSARTAN : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02408139, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-VALSARTAN HCT used for?
Treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. Not indicated for initial therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02408139 |
|---|---|
| Brand name | AURO-VALSARTAN HCT |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 25 MG VALSARTAN : 160 MG |
| Manufacturer | AURO PHARMA INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09DA03 VALSARTAN AND DIURETICS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Jun-2013 |
How is it administered?
Individualized by titration. Once stabilized on components, substitute with fixed combination once daily. Max dose: 320 mg valsartan / 25 mg hydrochlorothiazide. May be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to section 11 of full monograph), but typically store at 15-30°C.
How is it supplied?
Blisters of 2 x 14’s; HDPE containers of 30’s, 90’s, 100’s, 500’s, and 1000’s (varies by strength).
Contraindications
Hypersensitivity to components or sulfonamides; pregnancy/nursing; anuria; severe renal disease; hyponatremia; hypercalcemia; symptomatic hyperuricemia; concomitant aliskiren in diabetes/renal impairment.
Warnings and precautions
Fetal toxicity; angioedema; hypotension; non-melanoma skin cancer risk; photosensitivity; electrolyte imbalance; acute myopia/secondary angle-closure glaucoma.
What can be used instead?
Other Canadian products sharing ATC code C09DA03 VALSARTAN AND DIURETICS. 32 of 63 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-VALSARTAN HCT | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408120 |
| AURO-VALSARTAN HCT | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408147 |
| AURO-VALSARTAN HCT | 320 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408155 |
| AURO-VALSARTAN HCT | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408112 |
| DIOVAN-HCT | 12.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02241900 |
| DIOVAN-HCT | 12.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02308908 |
| DIOVAN-HCT | 160 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02241901 |
| DIOVAN-HCT | 25 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02246955 |
| DIOVAN-HCT | 25 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02308916 |
| SANDOZ VALSARTAN HCT | 12.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02356694 |
Who else supplies VALSARTAN AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VALSARTAN AND DIURETICS appears in 2425 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.